Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490447 | 0.93 | NAMPT (0.53) | NAMPTTDP1TP53 | |
| SCHEMBL1377890 | 0.92 | NAMPT (0.53) | NAMPTTDP1TP53 | |
| SCHEMBL1381498 | 0.92 | KCNJ1 (0.55) | NAMPTTDP1TP53 | |
| SCHEMBL1379247 | 0.88 | NAMPT (0.51) | NAMPTTDP1 | |
| SCHEMBL4498786 | 0.87 | NAMPT (0.53) | NAMPTTDP1TP53DHODH | |
| SCHEMBL1379608 | 0.85 | TDP1 (0.45) | NAMPTTDP1TP53 | |
| SCHEMBL1377354 | 0.84 | TP53 (0.51) | NAMPTTDP1TP53 | |
| SCHEMBL1377872 | 0.84 | KDM4E (0.55) | NAMPTTDP1TP53 | |
| SCHEMBL4506495 | 0.84 | TP53 (0.49) | NAMPTTDP1TP53DHODH | |
| SCHEMBL1379838 | 0.83 | HTT (0.57) | TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | claimed |
| US-7521448-B2 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1664021-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | KIT, CHUK, TNNI3K | NAMPT 588/4885TDP1 3696/4885TP53 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.